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The roles and actions of the tumor suppressor protein
p53 have been extensively studied with regard to nu-
clear events, including transcription and DNA damage
repair. However, the direct roles of p53 in mitochon-
drial DNA (mtDNA) replication and function are less
well understood. Studies herein used a mitochondrial-
targeted p53 (MTS-p53) to determine its effects on both
mtDNA abundance and mitochondrial function. MTS-
p53 decreased cellular proliferation and mtDNA abun-
dance in HepG2 cells transfected with wild-type (WT)
human p53. When MTS-p53 cells were treated with the
nucleoside reverse transcriptase inhibitor (NRTI), 2=,3=-
dideoxycytidine or 2=,3=-dideoxyinosine, mtDNA deple-
tion that resembled untransfected controls was ob-
served in both instances. p53-Overexpressing cells
showed reduced mitochondrial function by oximetry,
including a reduction in maximal respiratory capacity
and reserve capacity. A truncated p53 (MTS-p53-290)
was generated for localization exclusively to the mito-
chondria. MTS-p53-290 cells proliferated at control lev-
els but displayed decreased mtDNA abundance and mi-
tochondrial function with NRTI treatment. The MTS-
p53-290 cells demonstrated that only the nuclear
fraction of p53 controlled cellular proliferation, which
was supported by the MTS-p53 results. Data herein in-
dicate that overexpression of p53 in the mitochondria
reduces mtDNA abundance and increases the sensitivity
of mammalian cells to NRTI exposure by reducing mi-
tochondrial function. (Am J Pathol 2012, 180:2276–2283;
http://dx.doi.org/10.1016/j.ajpath.2012.01.045)
Tumor suppressor protein p53 is characterized as a
guardian of the genome, with various functions as a tran-
2276scription factor, DNA damage repair modulator, and sig-
naling protein.1–3 In addition to those nuclear functions,
p53 plays an important role in mitochondrial-mediated
cellular responses, including the binding of proteins lo-
calized to the outer mitochondrial membrane that initiates
apoptosis.4–7 Evidence has suggested that p53 is pres-
ent and functions in the mitochondrial matrix.8–11
Determination of the mitochondrial matrix localization
for native p53 has not been fully established. Mass spec-
trometry analysis of mitochondrial nucleoids failed to de-
tect the presence of p53,12,13 whereas others8–11 show
that p53 binds to mitochondrial DNA (mtDNA) and aids in
mtDNA repair. The p53 within the cell is helpful in main-
taining normal mitochondrial function because p53 in the
mitochondria enhances base excision repair of mtDNA
damage,9–11 and a loss of cellular p53 reduces mito-
chondrial function.14,15 Such enhancement of mtDNA re-
pair would have a positive impact on mitochondrial func-
tion and biogenesis.
Experiments herein were designed to determine the
role of p53 in the mitochondria of mammalian cells. To
accomplish this, a plasmid construct containing a mito-
chondrial-targeting sequence (MTS) ligated to the N-ter-
minus of the p53 protein (MTS-p53) was used to target
mitochondrial translocation of p53. Because of the strong
intrinsic nuclear localization of MTS-p53 as the result of
the sequence located in the 291 to 393 amino acid region
of p53, a second truncated construct of p53 (MTS-p53-
290) was generated to reduce nuclear localization of the
protein. The p53 translocated to the mitochondria in both
cases, with nuclear localization of p53 only seen in the
MTS-p53 construct. The mitochondrial-localized p53
overexpression resulted in depleted mtDNA abundance
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ment with pharmacological doses of nucleoside reverse
transcriptase inhibitors (NRTIs), 2=,3=-dideoxycytidine
(ddC) and 2=,3=-dideoxyinosine (ddI). Increased mito-
chondrial-targeted p53 negatively regulates mitochon-
drial function and mtDNA abundance, and our findings
suggest that one new role of p53 in the mitochondria is
the regulation of mitochondrial biogenesis.
Materials and Methods
Plasmid Construction and Transfection
A CMV vector plasmid containing WT human p53 (Clon-
tech, Mountain View, CA) was restricted with BamHI (Fer-
mentas, Glen Burnie, MD) and Eco0109I (New England
Biolabs, Ipswich, MA) to release the p53 insert and trun-
cate the stop codon. High-fidelity PCR using Pfx (Invitro-
gen, Grand Island, NY) was used to engineer an N-ter-
minal MTS and a C-terminal hemagglutinin (HA) tag onto
the p53 protein. The N-terminal primer was developed to
add the MTS of ornithine transcarbamylase to the N-termi-
nus of the p53 protein (sequence, 5=-GAGAGAGTCGACG-
CCACCATGCTGTTTAATCTGAGGATCCTGTTAAACAAT-
GCAGCTTTTAGAAATGGTCACAACTTCATGGTTCGAA-
ATTTTAAGCTTATGGAGGAGCCGCAG-3=). The C-terminal
primer was developed to add the HA tag to the C-termi-
nus of the p53 protein to enable discrimination of the
additional p53 from endogenous p53 (sequence, 5=-
TCTCTCGTCGACTCAAGCGTAGTCTGGGACGTCGTA-
TGGGTAGTCTGAGTCAGGCCCTTCTGTCTTGAACA-
TGAGTTT-3=). The resulting MTS-p53 construct was gel
purified and ligated back into the CMV vector plasmid
using blunt-end ligation. The resulting ligation product
was grown in NEB5 cells (New England Biolabs), which
were clonally selected, and the purified plasmid was
sequenced to ensure fidelity.
The MTS-p53-290 construct was generated using the
Stratagene QuikChange site-directed mutagenesis kit
(Agilent, Santa Clara, CA). BsiWI restriction enzyme sites
were introduced into the MTS-p53 construct at sites 290
to 291 and 391 to 392 using specially designed primers,
following the recommendations of the manufacturer. The
resulting plasmid was restricted with BsiWI (Fermentas)
to release the 291 to 391 region of p53 and ligated back
together. The resulting ligation product (termed MTS-
p53-290) was grown in NEB5 cells, which were clonally
selected, and the purified plasmid was sequenced to
ensure fidelity.
HepG2 cells were grown in Eagle’s minimal essential
medium (American Type Culture Collection, Manassas,
VA) with 10% fetal bovine serum (American Type Culture
Collection) and penicillin-streptomycin (Invitrogen) at
37°C and 5% CO2. Cells were transfected with either the
MTS-p53 or the MTS-p53-290 plasmid using the Fugene
6 transfection reagent (Roche, Indianapolis, IN) in a 3:1
ratio. Vector cells received only the CMV plasmid without
the MTS-p53. Cells were transfected for 24 hours, then
trypsinized and reseeded in Eagle’s minimal essential
medium containing 600 g/mL G418 (Lonza, Hopkinton,MA) to select for positive clones. After 14 days of G418
selection, colonies were selected using cloning cylinders
and were determined positive for the insert using primers
against the full-length region surrounding the MTS-p53 or
MTS-p53-290 insert (forward, 5=-TGGAAAAACGCCAG-
CAACGCG-3=; reverse, 5=-AAGGGATTTTGCCGATTTCG-
GAA-3=). Positive colonies were verified for protein pres-
ence and localization by standard SDS-PAGE and West-
ern blot protocols using an HA antibody (Sigma-Aldrich,
St. Louis, MO) for the MTS-p53 protein, human p53 anti-
body (Novus Biologicals, Littleton, CO) for the MTS-p53-
290 protein, succinate dehydrogenase subunit B
(Novus Biologicals) as a mitochondrial marker, and
lamin A (Sigma-Aldrich) as a nuclear marker. Subcel-
lular fractionation was achieved through differential
centrifugation after saponin treatment to permeabilize
the cell membrane.
Cell Viability
The following reagents were obtained through the AIDS
Research and Reference Reagent Program, Division of
AIDS, National Institute of Allergy and Infectious Dis-
eases, NIH: ddC (zalcitabine) and ddI (didanosine). Cells
were plated at 1  105 cells per well in a six-well dish.
Cells were allowed to proliferate for 24 hours in the ab-
sence of ddC or ddI. After the initial 24 hours, ddC (1.0 or
10.0 mol/L) or ddI (10.0 or 100.0 mol/L) was added to
the media, and the cells were collected and counted after
72 hours of additional growth. Cells were trypsinized and
counted using the trypan blue exclusion assay and a
hemocytometer.
mtDNA Abundance
Cells were plated at 1  105 cells per well in a six-well
dish. Cells were allowed to proliferate for 24 hours in the
absence of ddC or ddI. After the initial 24 hours, ddC
(0.1, 0.3, 1.0, 3.0, or 10.0 mol/L) or ddI (10, 30, or 100
mol/L) was added to the media, and the cells were
lysed after 24, 48, or 72 hours of growth using one times
Tris-EDTA with 30 g/mL of proteinase K (Invitrogen) and
0.5% SDS. Samples were allowed to lyse for 24 hours at
37°C. After lysis, the DNA was extracted from each sam-
ple using the MagNA Pure LC (Roche). The resulting
DNA samples were quantitated and analyzed for mtDNA
abundance using the Lightcycler 480 (Roche). Nuclear
DNA was amplified using the single-copy POLG2 nuclear
gene (forward, 5=-GAGCTGTTGACGGAAAGGAG-3=; re-
verse, 5=-CAGAAGAGAATCCCGGCTAA-3=), and mtDNA
was amplified using the COXI mitochondrial gene (for-
ward, 5=-TTCGCCGACCGTTGACTATT-3=; reverse, 5=-
AAGATTATTACAAATGCATGGGC-3=).
Oximetric Analysis
Oximetry and analysis were performed using an XF24
extracellular flux analyzer (Seahorse Bioscience, Bil-
lerica, MA) using methods described by the manufac-
turer. HepG2 vector, MTS-p53 clone 2 cells, and MTS-
p53-290 cells were seeded at 3  104 cells per well into
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lowed to grow for 24 hours in normal growth media. After
the initial 24 hours, cells were treated with ddC (0.1, 1.0,
or 10.0 mol/L) or ddI (1.0, 10.0, or 100.0 mol/L) for 24
or 72 hours. After 24 or 72 hours, media were aspirated
from the XF24 wells, unbuffered Dulbecco’s modified Ea-
gle’s medium (Seahorse Bioscience) was supplemented
with 4 mmol/L glucose (Sigma-Aldrich), and 1 mmol/L
sodium pyruvate (Sigma-Aldrich) was added to each
well. Cells were allowed to equilibrate in the new media
for 30 minutes before analysis by the XF24 system. Cells
were sequentially exposed to oligomycin (1 g/mL;
Sigma-Aldrich), fluoro-carbonyl cyanide phenylhydra-
zone (1.0 mol/L; Sigma-Aldrich), and rotenone (2.0
mol/L; Sigma-Aldrich) to determine cellular and mito-
chondrial oxygen consumption rates (OCRs). Data are
expressed as a percentage of the OCRs of the un-
treated controls. Results from these experiments were
used to determine basal respiration, proton leakage
(defined as the difference between basal respiration
OCR and nonmitochondrial OCR after rotenone treat-
ment), maximal respiration (defined as the maximum
OCR after fluoro-carbonyl cyanide phenylhydrazone
uncoupling), and reserve capacity (defined as the dif-
ference between the maximum respiration OCR and
the basal respiration OCR).
Statistical Analysis
All experiments were performed with n  3, with signifi-
cance determined using a one-way analysis of variance
or a two-tailed Student’s t-test, where appropriate, with
P  0.05 (GraphPad Prism, La Jolla, CA). A Tukey post
hoc test was performed for each data set, along with a
Figure 1. MTS-p53 and MTS-p53-290 construct map. The MTS of ornithine
transcarbamylase was added to the N-terminal side of human WT p53, and an
HA tag was added to the C-terminal side of p53 to discriminate between the
additional p53 from the endogenous p53. The shaded area shows the loca-
tion of the truncated 291 to 393 region of the MTS-p53-290 protein. The
constructs were placed under a CMV promoter and selected by geneticin in
HepG2 cells. a.a., amino acid.Grubbs test to determine outliers.Results
In the plasmid construct, the MTS of ornithine transcar-
bamylase was ligated to the N-terminus of the WT p53
protein (Figure 1), as previously used to translocate cy-
tosolic proteins into the mitochondria.16 The addition of a
C-terminal HA tag helped verify that p53 translocated to
the mitochondria and was separate from any endoge-
nous p53. Two clones expressed the MTS-p53–contain-
ing construct (Figure 2A). By using an HA antibody,
Western blot analyses were performed on fractionated
extracts. The MTS-p53 protein localized to the mitochon-
drial-enriched fraction and the nuclear fraction (Figure
2B). Both MTS-p53 clones 2 and 3 were used to reduce
misinterpretation of clonal expansion effects.
The cell viability and proliferation rates of the vector
and MTS-p53 cells were determined using the trypan
blue exclusion assay. The empty vector and both MTS-
p53 clones were seeded at the same initial cell density
and allowed to proliferate for 72 hours. After 72 hours,
both MTS-p53–overexpressing clones showed a signifi-
cant decrease (approximately 50%) in counted cells
compared with the vector clones (Figure 3A). There was
no change in cell viability (Figure 3B). Rates of doubling
revealed that MTS-p53 clones doubled at a slower rate
(clone 2, 20.7 hours; clone 3, 17.9 hours) compared with
empty vector controls (15.4 hours). This observed de-
crease correlated with the amount of p53 expressed in
the cells based on immunoblot analysis.
Figure 2. MTS-p53–overexpressing clones. The p53 clones were character-
ized by PCR genotyping and Western blot analysis. A:PCR genotyping dem-
onstrates that clones 2 and 3 were positive (Pos) for the MTS-p53 insert. Neg,
negative. B: SDS-PAGE and Western blot analysis show that p53 clones 2 and
3 expressed the MTS-p53 in both the nuclear and mitochondrial fraction. An
HA antibody was used to determine the amount of p53 produced from the
MTS-p53 construct, with succinate dehydrogenase subunit B (SDHB; a mi-
tochondrial marker) and lamin A (a nuclear marker) used as protein fraction
markers.
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depletion by adding NRTIs, ddC and ddI. Both of the
compounds have been used to treat patients with human
immunodeficiency virus 1 or are currently in use. These
NRTIs were toxic and caused severe mtDNA depletion.17
Doses used resemble those used in previous studies,18
and there was no appreciable decrease in cellular pro-
liferation at 72 hours after ddC or ddI, compared with
untreated controls (Figure 3, C and D). Neither ddC nor
ddI exposure reduced the viability of the cells (Figure 3,
E and F, respectively).
We focused on a possible contribution of the mitochon-
drial-targeted p53 to alterations in mtDNA abundance.
We analyzed the mtDNA abundance of all three clones
using real-time PCR. Results showed a modest, statisti-
cally significant, 25% decrease in mtDNA abundance in
both of the MTS-p53 cell lines when compared with the
controls (Figure 4A). These results demonstrate that over-
expression of p53 negatively affects the mtDNA abun-
dance in HepG2 cells. Treatment of the cells with ddC
decreased mtDNA abundance in both a dose- and time-
dependent manner (Figure 4, B–F). Depletion of mtDNA
became apparent after 24 hours of exposure at the low-
est doses of ddC, and mtDNA depletion worsened with
duration of exposure. A dose-dependent decrease in
mtDNA abundance resulted from ddI treatment after 72
hours (Figure 4, G and H). Overexpression of MTS-p53did not affect NRTI-induced mtDNA depletion, based on
either the concentration of NRTI treatment or the duration
of exposure. Overall, these data suggest that overexpres-
sion of p53 does not protect cells from ddC- or ddI-
induced mtDNA depletion at the doses used. Moreover,
NRTI-induced mtDNA depletion does not directly affect
cellular viability or cell proliferation.
To determine the effects of ddC and ddI on mitochon-
drial electron transport, we used an XF24 analyzer (Sea-
horse Bioscience) to measure cellular OCRs. The cells
were plated and exposed to ddC and ddI in a similar
manner to the mtDNA abundance experiments, although
only the vector and MTS-p53 clone 2 were used for these
experiments that determined cellular OCRs. After 24 or
72 hours of 10 mol/L ddC, a significant decrease in
basal respiration in the MTS-p53 clone was found (Figure
5A). There was no change in proton leakage, suggesting
the absence of apoptosis through the intrinsic pathway
(Figure 5B). Data suggest that mitochondrial permeabili-
zation is not increased and that MTS-p53 does not pro-
mote apoptosis of the cells after ddC exposure. In addi-
tion, there was a decrease in the maximal respiration of
the MTS-p53 clone and in the reserve capacity of the p53
clone after ddC (Figure 5, C and D, respectively). These
results show that p53 sensitizes the cells to ddC expo-
Figure 3. Cellular proliferation and viability of
MTS-p53 cells. Vector and MTS-p53 clones were
allowed to proliferate for 72 hours in either the
presence or the absence of ddC or ddI. Un-
treated MTS-p53 clones showed a decrease in
cellular proliferation compared with the vector-
only clone (A), whereas there was no increase in
cell death (B). The treatment of clones with ddC
over a broad range did not elicit a change in
either cell proliferation (C) or cell death (E) com-
pared with their untreated controls (C). The
treatment of clones with ddI over a broad range
also did not elicit a change in cell proliferation
(D) or cell death (F) compared with the un-
treated controls. *P  0.05.sure in an mtDNA-independent mechanism and that the
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after ddC treatment.
Similar results were seen with the ddI experiments,
although ddI had a more appreciable effect on mitochon-
drial OCR on the vector-only cells, compared with ddC.
There was no difference in basal respiration or proton
leakage after ddI (Figure 5, E and F). However, ddI re-
duced maximal respiration and reserve capacity in the
MTS-p53 clones (Figure 5, G and H). These data dem-
onstrate that overexpressing p53 sensitizes the cells to
NRTI exposure by reducing maximal respiration and re-
serve capacity.
To control for the nuclear localization of the MTS-p53
protein, a construct was generated to remove its nuclear
localization sequence. The nuclear localization sequence
is located in the 291 to 393 amino acid region of p53, and
we generated the second construct (termed MTS-p53-
290) to remove this region while still expressing the en-
zymatic and DNA-binding domains located in the 1 to
290 amino acid region.19,20 This construct retained the
original MTS from ornithine transcarbamylase to promote
mitochondrial localization. Immunoblots show that theMTS-p53-290 protein product was exclusively localized
to the mitochondrial compartment (Figure 6). Cell prolif-
eration studies revealed that the MTS-p53-290– trans-
fected cells proliferated at the same rate as the vector-
only cells, demonstrating that overexpression of p53 in
the nuclear compartment was responsible for the in-
creased doubling times seen in the MTS-p53 clones
(Figure 7A). There was no change in cell viability in
untreated cells (Figure 7B). Furthermore, there were no
changes seen in proliferation or viability after ddC (Figure
7, C and E, respectively) or ddI (Figure 7, D and F,
respectively) treatment, demonstrating that MTS-p53-290
does not affect proliferation or viability over the doses or
times studied.
Changes in mtDNA abundance were analyzed after
ddC and ddI exposure in the MTS-p53-290 cells. Similar
to the MTS-p53 cells, MTS-p53-290 cells showed a re-
duction in mtDNA abundance in untreated cells when
compared with vector-only cells (Figure 8A). There was a
40% reduction in mtDNA abundance in MTS-p53-290
cells when compared with controls. When treated with
Figure 4. The mtDNA abundance in MTS-p53
cells. The vector (Vec) and MTS-p53 clones were
treated with either ddC or ddI for 24, 48, or 72
hours and then lysed to analyze mtDNA abun-
dance by real-time PCR. A: Untreated MTS-p53
clones showed a decrease in mtDNA abundance
compared with the vector-only controls (C). Expo-
sure to ddC elicited a dose-dependent reduction at
24 hours (B), 48 hours (C), and 72 hours (D) in
mtDNA abundance in MTS-p53 and empty vector
cells. There was no difference in the rate of mtDNA
depletion after 1.0 mol/L (E) or 10.0 mol/L (F)
of ddC exposure in MTS-p53 or vector cells. Similar
dose-dependent results could be seen after ddI
exposure (G), with no differences between vector
and MTS-p53 cells (H). *P  0.05.ddC or ddI, data show a dose-dependent decrease in
en durin
normali
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ddI, and this effect was independent of p53 abundance
in the mitochondria (Figure 8, B and C, respectively).
There was no statistical difference between MTS-p53-290
mtDNA abundance after ddC or ddI treatment when com-
pared with similar doses in control cells. These studies
show that overexpression of p53 in the mitochondria
does not protect cells from ddC- or ddI-induced mtDNA
depletion at the doses used, similar to results seen in the
MTS-p53 cells.
Finally, oxygen consumption measurements were per-
formed on the MTS-p53-290 cells. Experiments showed
that MTS-p53-290 cells were sensitized to ddC and ddI at
the highest doses used. Overexpression of p53 in the
mitochondria reduced basal respiration, maximal respi-
ration, and reserve capacity after ddC and ddI exposure,
whereas vector cells remained unchanged (Figure 9).
There was no change in proton leakage after ddC or ddI
treatment. These experiments demonstrate that p53 in
the mitochondria sensitizes the cells to NRTI exposure,
Figure 5. The OCRs of MTS-p53 cells. Vector (Vec) and p53 clone 2 mitocho
ddC (A–D) or ddI (E–H) for 24 or 72 hours and then analyzed for OCR. MT
whereas ddI elicited a small, but not statistically significant, decrease in bas
exposure, suggesting no increase in mitochondrial permeabilization, often se
(C and G, respectively) and reserve capacity (D and H, respectively) when
Figure 6. MTS-p53-290 subcellular localization. The 291 to 393 amino acid
region of WT human p53 was truncated as described in Materials and
Methods. This construct contains the MTS from ornithine transcarbamylase.
The reduced size of the MTS-p53-290 protein produced a unique band that
was easily differentiated from WT p53. Subcellular fractionation revealed that
the MTS-p53-290 protein localized exclusively to the mitochondrial fraction,
with no visible MTS-p53-290 protein in the nuclear fraction. A human p53
antibody was used to determine the amount of p53 produced from the
MTS-p53-290 construct, with succinate dehydrogenase subunit B (SDHB; a
mitochondrial marker) and lamin A (a nuclear marker) used as protein
fraction markers.independent of changes in mtDNA abundance, by re-
ducing electron transport function.
Discussion
This work demonstrates that overexpression of p53 neg-
atively affects the normal mitochondrial homeostasis in
unction was determined using an XF24 flux analyzer. Cells were treated with
ells showed a marked decrease in basal respiration after ddC treatment (A),
ation (E). There was no change in proton leakage after ddC (B) or ddI (F)
g apoptosis. Both ddC and ddI significantly reduced the maximal respiration
zed to untreated cells. *P  0.05.
Figure 7. Cellular proliferation and viability of MTS-p53-290 cells. Vector
(Vec) and MTS-p53-290 clones were allowed to proliferate for 72 hours in
either the presence or the absence of ddC or ddI. Untreated MTS-p53-290
cells showed no change in cellular proliferation (A) or viability (B) compared
with the vector-only cells. Treatment of cells with ddC did not elicit a change
in either cell proliferation (C) or cell death (E) compared with their untreatedndrial f
S-p53 c
al respircontrols (C). Treatment of cells with ddI also did not elicit a change in cell
proliferation (D) or cell death (F) compared with the untreated controls.
results c
.05.
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sensitivity to NRTIs that deplete mtDNA. p53 Has been
studied extensively in the nucleus and cytosol, whereas
the mitochondrial role of p53 has focused on a mem-
brane-bound fraction and its role in promoting apopto-
sis.4–7 The constructs used herein in experiments were
designed to minimize overexpression of p53 in the nu-
Figure 8. The mtDNA abundance in MTS-p53-290 cells. Vector and MTS-p53
to analyze mtDNA abundance. A: Untreated MTS-p53-290 cells showed a
Exposure to ddC elicited a reduction in mtDNA abundance in MTS-p53-290
after 1.0 or 10.0 mol/L of ddC exposure in the p53 of vector cells. Similar
vector and the MTS-p53-290 cells at any of the times or doses used. *P  0
Figure 9. The OCRs of MTS-p53-290 cells. Vector (Vec) and MTS-p53-290
mitochondrial function was determined using an XF24 flux analyzer. Cells
were treated with ddC (A–D) or ddI (E–H) for 72 hours and then analyzed for
OCRs. MTS-p53-290 cells displayed decreased basal respiration after ddC (A)
and ddI (E) treatment. There was no change in proton leakage after ddC (B)
or ddI (F) exposure. Both ddC and ddI significantly reduced the maximal
respiration (C and G, respectively) and reserve capacity (D and H, respec-
tively) when normalized to untreated cells. *P  0.05.cleus of the cells and maximize mitochondrial localiza-
tion. We found that the MTS used was not strong
enough to completely overcome the nuclear localiza-
tion inherent to p53.19,20 This resulted in overexpres-
sion of p53 in both the nuclear and mitochondrial frac-
tions, with each fraction contributing to the observed
results in the MTS-p53 studies. Truncation of the 291 to
391 portion of p53, along with attachment of an MTS,
enabled selective localization of the MTS-p53-290 protein
to the mitochondria and further discrimination of the re-
sults seen in the MTS-p53 studies. The MTS-p53-290
studies allowed us to discriminate the results of the MTS-
p53 studies into those relating to nuclear overexpression
of p53 and mitochondrial overexpression of p53.
Results showed that overexpression of MTS-p53 de-
creased cell proliferation (Figure 3A). This effect can be
attributed to the nuclear fraction of the MTS-p53 protein
because a decrease in cellular proliferation was not seen
in the MTS-p53-290 cells (Figure 7A). We also found no
change in cellular proliferation or viability in either p53
cell after ddC or ddI treatment. Because both of these
compounds are mitochondrial toxic and did not
change proliferation or viability, these data validate
that the decrease in cellular proliferation was a contri-
bution of the nuclear p53 and not a result of mitochon-
drial-localized p53.
Overexpression of the p53 constructs used in these
experiments decreased mtDNA abundance (Figures 4A
and 8A). The manner in which p53 is able to reduce
mtDNA abundance is unknown. Previous work14 has
shown that decreased levels of p53 lead to a decrease in
mtDNA abundance, whereas in our research, higher lev-
els of p53 can lead to a decrease in mtDNA abundance.
These results could be explained by the difference in
functions and subcellular localization of the p53 protein.
Because of p53’s transcription factor activity in the nu-
cleus, a loss of p53 in the nucleus would reduce mito-
chondrial proteins required for mtDNA maintenance. In
our studies, because there is no change in nuclear p53
status in the MTS-p53-290 clones, there would be no
changes in the nuclear transcriptional activity of the en-
dogenous p53. The MTS-p53-290 cells enable for the
elucidation of the mitochondrial p53 function, indepen-
dent of previous studies of nuclear p53 functions. These
nes were treated with either ddC or ddI for 24, 48, or 72 hours and then lysed
crease in mtDNA abundance compared with the vector-only controls (C).
ty vector cells (B). There was no difference in the rate of mtDNA depletion
ould be seen after ddI exposure (C), with no statistical differences between-290 clo
40% de
and empfindings would implicate an inherent p53 activity that
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p53-290 cells as a result of mitochondrial expression.
There is the possible role of p53’s exonuclease func-
tion negatively affecting mtDNA abundance. The p53 has
had an intrinsic 3= to 5= exonuclease function that can be
used to aid in base excision repair.9,21 This presents at
least three possibilities. In the first case, p53 may be
aiding the repair of endogenous damage present in
mtDNA. In this case, more complete copies of mtDNA
would enable quicker transcription of electron transport
proteins to meet energy demands. This would require a
smaller pool of low-damage mtDNA that can be used
more efficiently than higher-damage mtDNA but would
make that smaller pool of mtDNA more susceptible to
mtDNA genotoxic stress, as seen after ddC and ddI
exposure. The second possibility is that p53’s exonu-
clease activity is promoting digestion of more damaged
copies of mtDNA. Previous work22 has shown that over-
expression of robust exonuclease function of exonu-
clease III in the mitochondria can lead to mtDNA deple-
tion and initiate cell death. However, we do not see any
changes in cell viability and we do not know the levels of
damage present in these cells. The final possibility is an
unknown mitochondrial function of p53 for negatively reg-
ulating mtDNA abundance.
Oximetry demonstrated that p53 sensitized the cells to
ddC and ddI treatment. These changes in OCR are at-
tributed to the mitochondrial fraction of p53. ddC and ddI
are known inhibitors of mtDNA replication, the primary
cause of their toxicity in humans.17 The diminished OCR
in the p53 clone after ddC and ddI suggests a threshold
effect for mtDNA depletion. The MTS-p53 clones exhib-
ited a 25% decrease in mtDNA compared with the vector
clones, whereas the MTS-p53-290 cells exhibited a 40%
decrease in mtDNA compared with the vector clones.
Treatment with ddC or ddI caused a significant depletion
of mtDNA at each dose. Once mtDNA depletion reaches
a functional threshold, mitochondrial electron transport
defects may result from depleted mtRNA and lower mi-
tochondrial protein abundance.
Our results show that mitochondrial overexpression of
p53 leads to decreased mitochondrial function and di-
minished mtDNA abundance. The mechanism of p53’s
control of mitochondrial electron transport and cellular
energetics is important for understanding the changes in
mitochondrial function after cellular stresses, such as
oxidative stress or antiretroviral therapies. Delineating the
function of each localized fraction of p53 will help deter-
mine p53’s contribution to mtDNA abundance and oxida-
tive phosphorylation.
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